Natera. has filed a patent for a method to determine fetal chromosome ploidy status using genotypic data from mixed DNA samples. The system involves sequencing DNA molecules from both mother and fetus, comparing allelic distributions, and using a joint distribution model for accurate ploidy determination. GlobalData’s report on Natera gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Natera Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Natera, AI-assisted genome sequencing was a key innovation area identified from patents. Natera's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Determining fetal ploidy status using genotypic data

Source: United States Patent and Trademark Office (USPTO). Credit: Natera Inc

The patent application (Publication Number: US20240038328A1) describes a system for measuring the amount of DNA from one individual in a biological sample of another individual. The system includes a sequencer that sequences DNA molecules derived from both individuals, obtained through targeted multiplex amplification of polymorphic loci. A computer processor then quantifies the sequencing reads corresponding to each allele at the polymorphic loci to measure the amount of DNA from the first individual in the sample of the second individual. The sequencer performs high-throughput sequencing, and the DNA molecules may contain sequencing tags, sample indexes for multiplex sequencing, or molecular barcodes for identification purposes.

Furthermore, the system can be applied to various biological samples such as blood, serum, plasma, or urine, with the first individual being identified as a fetus or a transplant. The polymorphic loci targeted for amplification can include SNP loci or indel loci, ranging from 50 to 20,000 loci. The efficiency of the system is highlighted by the requirement that a significant percentage of sequencing reads map to the polymorphic loci, ensuring accurate measurement of DNA from the first individual in the sample of the second individual. Additionally, the system allows for the identification of sequencing reads originating from the same original DNA molecule, enhancing the precision of the measurement process.

To know more about GlobalData’s detailed insights on Natera, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies